First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study

Background: The long overall survival (OS) observed among patients with non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression in chemoimmunotherapy (CIT) groups in previous phase III trials suggests the limited efficacy of CIT among the subgroup with ≤49% PD-L1 ex...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-10, Vol.15 (20), p.4988
Hauptverfasser:	Tanimura, Keiko, Takeda, Takayuki, Kataoka, Nobutaka, Yoshimura, Akihiro, Nakanishi, Kentaro, Yamanaka, Yuta, Yoshioka, Hiroshige, Honda, Ryoichi, Uryu, Kiyoaki, Fukui, Mototaka, Chihara, Yusuke, Takei, Shota, Kawachi, Hayato, Yamada, Tadaaki, Tamiya, Nobuyo, Okura, Naoko, Yamada, Takahiro, Murai, Junji, Shiotsu, Shinsuke, Kurata, Takayasu, Takayama, Koichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Apoptosis Cancer Cancer therapies Care and treatment Chemotherapy Clinical trials Comparative analysis Death Development and progression Hospitals Immune checkpoint inhibitors Immunotherapy Ipilimumab Ligands Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Medical prognosis Medical research Medicine, Experimental Non-small cell lung carcinoma Patients PD-L1 protein Pemetrexed Platinum Small cell lung carcinoma Software Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!